Koninklijke Philips N.V.
NYSE:PHGMedical - Devices
+$0.57 today
- Market cap
- $29.11B
- Beta
- 0.93
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.02
- Dividend yield
- 3.62%
Volume 1.45M
Average 1.17M
PHG EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Koninklijke Philips N.V.NYSE: PHG
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of €1.02B rose 49.6% year over year, behind the +62.1% change in trailing-twelve-month EBITDA. Sequentially, it rose 90.0% from the prior quarter. Over 3 fiscal years it compounded at +184.2% a year.
Context
- EBITDA amounted to 14.8% of revenue in FY2025, up 4.5 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of €3.59B (+36.0%) for the fiscal year ending Dec 2026, a slowdown from the +42.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- €1.02B+90.0% QoQ
- Last fiscal yearDec 2025
- €2.64B+42.7% YoY
- LTMJun 2026
- €3.05B+62.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +49.6% | +28.7% | -20.9 pp |
| 1 year | +42.7% | +36.0% | -6.8 pp |
| 3-year CAGR | +184.2% | +12.5% | -171.6 pp |
| 5-year CAGR | +9.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
EUR · from the income statement
- Latest · FY2025
- 2.64B EUR
- Year-over-year change
- +42.7%
- 4-year CAGR
- +7.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.64B | +42.7% |
| FY2024 | 2024-12-31 | 1.85B | +77.6% |
| FY2023 | 2023-12-31 | 1.04B | +805.2% |
| FY2022 | 2022-12-31 | 115M | -94.2% |
| FY2021 | 2021-12-31 | 2B | — |
EBITDA vs competitors
How PHG compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +62.1% is the 2nd highest of 10, against a peer median of +9.8%.
- EBITDA amounts to 17.3% of revenue for PHG, versus a peer median of 21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B USD | +9.8% | +4.1% | 27.3% | |
| LTM Sep 2026 | $9.71B USD | -17.7% | +0.1% | 20.1% | |
| LTM Jun 2026 | $5.8B USD | +23.2% | +23.0% | 27.6% | |
| LTM Jun 2026 | $3.07B USD | -19.7% | +6.1% | 15.2% | |
| LTM Jun 2026 | €3.05B EUR | +62.1% | +184.2% | 17.3% | |
| LTM Jun 2026 | $2.17B USD | +12.7% | +16.5% | 38.3% | |
| FY2025 | $1.34B USD | +0.1% | +5.1% | 21.7% | |
| LTM Sep 2026 | $211.36M USD | +363.4% | — | 14.0% | |
| LTM Mar 2026 | $32.23M USD | +25.1% | +22.2% | 37.4% | |
| LTM Mar 2026 | -$13.84M USD | +3.2% | — | 13.9% | |
| Peer median (excluding PHG) | — | +9.8% | +6.1% | 21.7% | |
Competitors are the stored peer set for PHG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.16B | 17.83B | 18.17B | 18.02B | 17.83B |
| Cost of Revenue | 9.99B | 10.63B | 10.72B | 10.25B | 9.78B |
| Gross Profit | 7.17B | 7.19B | 7.45B | 7.77B | 8.06B |
| Gross Margin | 41.8% | 40.4% | 41.0% | 43.1% | 45.2% |
| Research & Development | 1.81B | 2.09B | 1.89B | 1.75B | 1.7B |
| Selling, General & Admin | 4.86B | 5.29B | 5.13B | 5.07B | 4.97B |
| Operating Expenses | 6.62B | 8.72B | 7.56B | 7.24B | 6.63B |
| Depreciation & Amortization | 1.32B | 1.6B | 1.26B | 1.39B | 1.13B |
| EBITDA | 2B | 115M | 1.04B | 1.85B | 2.64B |
| EBITDA Margin | 11.6% | 0.6% | 5.7% | 10.3% | 14.8% |
| Operating Income | 553M | (1.53B) | (115M) | 529M | 1.42B |
| Operating Margin | 3.2% | -8.6% | -0.6% | 2.9% | 8.0% |
| Interest Income | 18M | 25M | 46M | 79M | 108.54M |
| Interest Expense | 164M | 244M | 306M | 337M | 332.34M |
| Other Income / Expenses | (44M) | (202M) | (412M) | (406M) | (242M) |
| Income Before Tax | 509M | (1.73B) | (527M) | 123M | 1.18B |
| Pre-Tax Margin | 3.0% | -9.7% | -2.9% | 0.7% | 6.6% |
| Income Tax Expense | (103M) | (113M) | (73M) | 963M | 282M |
| Net Income | 3.32B | (1.61B) | (466M) | (702M) | 895M |
| Net Margin | 19.3% | -9.0% | -2.6% | -3.9% | 5.0% |
| EPS (Basic) | 0.67 | (1.68) | (0.49) | (0.75) | 0.95 |
| EPS (Diluted) | 0.64 | (1.68) | (0.49) | (0.75) | 0.93 |
| Weighted Avg Shares | 907.46M | 952.46M | 948.79M | 933.37M | 962.37M |
| Weighted Avg Shares (Diluted) | 950.28M | 952.46M | 948.79M | 933.37M | 962.5M |
Koninklijke Philips N.V.
NYSE:PHG
Intrinsic Alpha fair value
Locked
Current Price
$29.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.